Designing vaccines against viruses or tumor cells that elicit CD8 T cell responses depends on understanding how viral and tumor antigens initiate activation of nai?½ve CD8 T cells. In his Perspective, [Ploegh][1] explores several studies published here ([ Norbury et al .][2], [ Wolkers et al .][3]) and elsewhere that reveal the pathway from viral or tumor antigens to long-lived peptides that are capable of priming CD8 T cells. [1]: http://www.sciencemag.org/cgi/content/full/304/5675/1262 [2]: http://www.sciencemag.org/cgi/content/short/304/5675/1318 [3]: http://www.sciencemag.org/cgi/content/short/304/5675/1314
No takes yet. Share an insight, caveat, or question.
Hidde L. Ploegh (2004) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: